Concord Drugs Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 82.65 as of 06 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 15.2 on March 2022 to 16.5 on March 2021 . This represents a CAGR of 1.65% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 231.35 crore on March 2022 to ₹ 176.64 crore on March 2021 . This represents a CAGR of -5.25% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Sakar Healthcare Ltd for the Dec '25 is ₹ 70.85 crore as compare to the Sep '25 revenue of ₹ 58.78 crore. This represent the growth of 20.53% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Sakar Healthcare Ltd for the Dec '25 is ₹ 19.1 crore as compare to the Sep '25 ebitda of ₹ 12.57 crore. This represent the growth of 51.95% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 10.25 crore over 7 quarters. This represents a CAGR of 128.70% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Concord Drugs Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Sakar Healthcare Ltd?

Market cap of Concord Drugs Ltd is 108 Cr while Market cap of Sakar Healthcare Ltd is 1,330 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Sakar Healthcare Ltd?

The stock performance of Concord Drugs Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Sakar Healthcare Ltd?

As of May 6, 2026, the Concord Drugs Ltd stock price is INR ₹82.65. On the other hand, Sakar Healthcare Ltd stock price is INR ₹598.0.

How do dividend payouts of Concord Drugs Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.